Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats.
Knezevic. Mario M; Gojkovic. Slaven S; Krezic. Ivan I; Zizek. Helena H; Vranes. Hrvoje H; Malekinusic. Dominik D; Vrdoljak. Borna B; Knezevic. Tamara T; Horvat Pavlov. Katarina K; Drmic. Domagoj D; Staroveski. Miro M; Djuzel. Antonija A; Rajkovic. Zoran Z; Kolak. Toni T; Lovric. Eva E; Milavic. Marija M; Sikiric. Suncana S; Barisic. Ivan I; Tepes. Marijan M; Tvrdeic. Ante A; Patrlj. Leonardo L; Strbe. Sanja S; Sola. Marija M; Situm. Andrej A; Kokot. Antonio A; Boban Blagaic. Alenka A; Skrtic. Anita A; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 (10 µg/kg i.p.) re‑established blood flow through collateral veins after complete superior mesenteric vein occlusion.
- The peptide reduced portal, caval and intracranial hypertension, prevented arterial hypotension and normalized ECG patterns.
- It markedly lowered tissue oxidative stress and prevented multi‑organ damage (heart, lung, liver, kidney, gut, brain).
Practical Outcomes
- For biohackers, this study suggests BPC‑157 could be a powerful tool for repairing severe vascular or gut injuries and reducing related organ stress. However, the data are from rats, so human dosing and safety are still unknown; any use should be experimental, low‑dose, and under medical supervision.
Summary
In rats where the main vein draining the gut was completely blocked, a single low dose of the peptide BPC‑157 quickly opened up backup blood‑vessel routes, restored blood flow, lowered dangerous pressure spikes, and prevented damage to the heart, lungs, liver, kidneys, gut and brain.
Abstract
<b>Background</b>. Gastric pentadecapeptide BPC 157 therapy in rats compensated irremovable occlusion of various vessels and counteracted the consequent multiorgan dysfunction syndromes by activation of the corresponding collateral bypassing loops. Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein. <b>Methods</b>. Assessments, for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, and oxidative stress) include the portal and caval hypertension, aortal hypotension, and centrally, the superior sagittal sinus hypertension, systemic arterial and venous thrombosis, ECG disturbances, MDA-tissue increase, and heart, lung, liver, kidney and gastrointestinal tract, in particular, and brain (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus) lesions. Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time. <b>Results</b>. BPC 157 rapidly activated the superior mesenteric vein-inferior anterior pancreati-coduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, reestablished superior mesenteric vein and portal vein connection and reestablished blood flow. Simultaneously, toward inferior caval vein, an additional pathway appears via the inferior mesenteric vein united with the middle colic vein, throughout its left colic branch to ascertain alternative bypassing blood flow. Consequently, BPC 157 acts peripherally and centrally, and counteracted the intracranial (superior sagittal sinus), portal and caval hypertension, aortal hypotension, ECG disturbances attenuated, abolished progressing venous and arterial thrombosis. Additionally, BPC 157 counteracted multiorgan dysfunction syndrome, heart, lung, liver, kidney and gastrointestinal tract, and brain lesions, and oxidative stress in tissues. <b>Conclusion</b>. BPC 157 therapy may be specific management also for the superior mesenteric vein injuries.
Study Information
pubmed
2021
2021-08-17T00:00:00.000Z
10.3390/biomedicines9081029
27
75